Cancer Chemotherapy and Pharmacology

, Volume 36, Issue 5, pp 425–430

Clinical pharmacology of cytarabine in patients with acute myeloid leukemia: a Cancer and Leukemia Group B study

Authors

  • Ronald A. Fleming
    • Medical Center BoulevardComprehensive Cancer Center of Wake Forest University
  • Robert L. Capizzi
    • Medical Center BoulevardComprehensive Cancer Center of Wake Forest University
  • Gary L. Rosner
    • Duke University Medical Center
  • Lawrence K. Oliver
    • The Upjohn Company
  • Stephen J. Smith
    • Medical Center BoulevardComprehensive Cancer Center of Wake Forest University
  • Charles A. Schiffer
    • University of Maryland Cancer Center
  • Richard T. Silver
    • The New York Hospital
  • Bruce A. Peterson
    • University of Minnesota Medical School
  • Raymond B. Weiss
    • Walter Reed Army Medical Center
  • George A. Omura
    • The University of Alabama at Birmingham
  • Robert J. Mayer
    • Dana-Farber Cancer Institute
  • David A. Van Echo
    • University of Maryland Cancer Center
  • Clara D. Bloomfield
    • Roswell Park Cancer Institute
  • Richard L. Schilsky
    • Cancer Research CenterUniversity of Chicago
Original Article Cytarabine, Leukemia

DOI: 10.1007/BF00686192

Cite this article as:
Fleming, R.A., Capizzi, R.L., Rosner, G.L. et al. Cancer Chemother. Pharmacol. (1995) 36: 425. doi:10.1007/BF00686192

Abstract

The pharmacokinetics of cytarabine (ara-C) were determined in 265 patients with acute myeloid leukemia (AML) receiving ara-C (200 mg/m2 per day for 7 days as a continuous infusion) and daunorubicin during induction therapy. The mean (standard deviation) ara-C concentration at steady-state (Css) and systemic clearance (Cl) were 0.30 (0.13) μM and 134 (71) l/h per m2 respectively. Males had a significantly faster ara-C Cl (139 vs 131 l/h per m2,P=0.025) than females. Significant correlations were noted between ara-C Cl and the pretreatment, peripheral white blood cell count (P=0.005) and pretreatment blast count (P=0.020). No significant differences in ara-C Css or Cl were noted in patients achieving complete remission compared with those failing therapy (P=0.315,P=0.344, respectively). No significant correlations were observed between ara-C pharmacokinetic parameters and several indices of patient toxicity. Our findings indicate that variability in ara-C disposition in plasma at this dosage level does not correlate with remission status or toxicity in patients with AML receiving initial induction therapy with ara-C and daunorubicin.

Key words

CytarabineLeukemia

Copyright information

© Springer-Verlag 1995